GLOW LIFETECH CORP. (9DO.HM)
Chart Events
Performance Outlook
| Previous Close | 0.0510 |
| Open | 0.0510 |
| Bid | 0.0510 x N/A |
| Ask | 0.0560 x N/A |
| Day's Range | 0.0510 - 0.0510 |
| 52 Week Range | 0.0390 - 0.0932 |
| Volume | |
| Avg. Volume | 47 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Glow Launches New Brand Identity to Underscore Its High-Performance, Technology-Driven Portfolio of Natural Ingredients
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company"), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to announce the unveiling of its new brand identity going live today. As the Company advances its commercial plans, Glow is introducing a full top-to-bottom redesign of its logo, colour palette, packaging, marketing materials, and launching a new website, www.glowlif
- Newsfile
Glow LifeTech Completes Development of Proprietary MyCell Liquid Cannabis Ingredients; Advances Plans to Launch in Canadian Market
Toronto, Ontario--(Newsfile Corp. - November 1, 2022) - Glow LifeTech Corp. (CSE: GLOW) (OTCQB: GLWLF) (FSE: 9DO) ("Glow" or the "Company"), a biotech innovator producing next-generation, science-backed natural ingredients, is pleased to announce the completion of development of its proprietary MyCell® liquid cannabis ingredients, including THC and CBD. The Company now plans for commercialization in the Canadian market, given product readiness. The successful development of MyCell® liquid water-
- Newsfile
Glow LifeTech Reports Positive Preliminary Results from Clinical Study of Artemic Support(R) on Patients with Long COVID Syndrome
Clinical Study results indicate the potential ability of Glow Lifetech's ArtemiC Support® to reduce symptoms of Post-Acute COVID Syndrome (Long COVID).Study results demonstrate the statistically significant reduction in severity of a range of Long COVID symptoms, including Dyspnea (shortness of breath), Cough, Asthenia (physical weakness/lack of energy), Headache and Mental Confusion.150 Patients were administered ArtemiC Support® during a 6-week period under the supervision of their doctor, wit
